AUROPHARMA stock
AUROPHARMA is showing a constructive news setup around Pharmaceuticals, with 9 recent stories and improving sentiment breadth.
AUROPHARMA has built a constructive coverage cluster in the last 29 days. The strongest recurring theme is Pharmaceuticals, while the current weighted impact score is +57 from 8 bullish, 1 bearish, and 0 neutral stories across 3 sources.
AUROPHARMA is last saved at ₹1,700 with a day move of +0.00%. That quote should be read with the article tape: a positive headline only matters if price, volume, and follow-through confirm it; a negative headline matters more when it keeps repeating across multiple publishers.
AUROPHARMA has filed its latest quarterly results. The company reported a revenue of Rs 7978.52 crore and a profit of Rs 843.98 crore. This information is now on record for public review. This hub keeps the permanent stock view separate from short-lived article pages, so search engines and users get one accumulated view instead of scattered programmatic summaries.
Economic Times · 20 days ago · 2 min read
Economic Times · 25 days ago · 2 min read
Economic Times · 18 Sept 2026 · 2 min read
Economic Times · 16 Sept 2026 · 2 min read
Mint · 15 Sept 2026 · 2 min read
How AUROPHARMA stacks against related names in this news cluster
AUROPHARMA has appeared across 9 recent stories from 3 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.
AUROPHARMA coverage is currently leaning bullish, with 8 bullish, 1 bearish, and 0 neutral analyzed stories in the recent window.
Recent AUROPHARMA coverage is clustering around Pharmaceuticals and Pharma. Related names showing up alongside AUROPHARMA include SUNPHARMA, BAJAJ-AUTO, BHARATFORG.
Use this page as a coverage hub for AUROPHARMA: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.
5 recent mentions linked to AUROPHARMA
TopicPharma4 recent mentions linked to AUROPHARMA
StockSUNPHARMARelated news cluster with 2 links
Latest storyBullish for Pharma: US Exempts India from Specialty Drug TariffsThis news provides a positive regulatory signal for the Indian pharma sector, which has been navigat
How retail crowds and channels are talking about AUROPHARMA right now — context for your own research, not a trade call.